About The Study: Hospitals and health systems administered more than 158,000 anti–SARS-CoV-2 monoclonal antibodies (mAbs) doses in early 2022 despite Food and Drug Administration (FDA) deauthorization because of a lack of efficacy against the Omicron variant. Medicare payments for mAb administration range from $450 to $750 per dose, indicating that spending on these deauthorized treatments likely exceeds $71 million. The findings suggest that the use of deauthorized mAb products was widespread, even though patients had a minimal likelihood of benefit.
Authors: Timothy S. Anderson, M.D., M.A.S., of Beth Israel Deaconess Medical Center in Boston, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2022.28997)
